Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study von Rudin, Charles M, Prof, Pietanza, M Catherine, MD, Bauer, Todd M, MD, Ready, Neal, Prof, Morgensztern, Daniel, MD, Glisson, Bonnie S, Prof, Byers, Lauren A, MD, Johnson, Melissa L, MD, Burris, Howard A, MD, Robert, Francisco, Prof, Han, Tae H, PhD, Bheddah, Sheila, BA, Theiss, Noah, MS, Watson, Sky, BS, Mathur, Deepan, MD, Vennapusa, Bharathi, MD, Zayed, Hany, PhD, Lally, Satwant, MS, Strickland, Donald K, MD, Govindan, Ramaswamy, Prof, Dylla, Scott J, PhD, Peng, Stanford L, MD, Spigel, David R, MD

Volltext

Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia von WING LEUNG, HUDSON, Melissa M, RAZZOUK, Bassem I, MATHEW, Prasad, SHEARER, Patricia, EVANS, William E, PUI, Ching-Hon, STRICKLAND, Donald K, PHIPPS, Sean, SRIVASTAVA, Deo K, RIBEIRO, Raul C, RUBNITZ, Jeffrey E, SANDLUND, John T, KUN, Larry E, BOWMAN, Laura C

Volltext

ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology von Bauer, Todd M., Spigel, David, Ready, Neal, Morgensztern, Daniel, Glisson, Bonnie S., Byers, Lauren A., Burris, Howard, Robert, Francisco, Strickland, Donald K., Pietanza, Maria C., Govindan, Ramaswamy, Dylla, Scott J., Peng, Stanford, Rudin, Charles

Volltext

The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort von Castellino, Sharon, Lensing, Shelly, Riely, Caroline, Rai, Shesh N., Davila, Rene, Hayden, Randall T., Fleckenstein, Jackie, Levstik, Mark, Taylor, Shari, Dean, Patrick J., Kippenbrock, Sarah, Pope, Jennifer, Carr, Jeanne, Strickland, Donald K., Hudson, Melissa M.

Volltext

Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: an institutional experience and review of the literature von Gow, Kenneth W, Lensing, Shelly, Hill, D.Ashley, Krasin, Matthew J, McCarville, M.Beth, Rai, Shesh N, Zacher, Margie, Spunt, Sheri L, Strickland, Donald K, Hudson, Melissa M

Volltext

Hepatitis C infection and hepatocellular carcinoma after treatment of childhood cancer von STRICKLAND, Donald K, JENKINS, Jesse J, HUDSON, Melissa M

Volltext

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Th... von Donnellan, William B., Atallah, Ehab L., Asch, Adam S., Patel, Manish R., Yang, Jay, Eghtedar, Alireza, Borthakur, Gautam M., Charlton, Julie, MacDonald, Alexander, Korzeniowska, Anna, Sainsbury, Elizabeth, Strickland, Donald K., Jones, Suzanne, Overend, Philip, Adelman, Carrie A., Fabbri, Giulia, Travers, Jon, Smith, Simon, Pease, J. Elizabeth, Cosaert, Jan

Volltext

A phase I, open-label, first-time-in-patient dose escalation and expansion study to assess the safety, tolerability, and pharmacokinetics of nanoparticle encapsulated Aurora B kina... von Burris, Howard A., Wang, Judy Sing-Zan, Johnson, Melissa Lynne, Falchook, Gerald Steven, Jones, Suzanne Fields, Strickland, Donald K, Greenlees, Carol, Brugger, Wolfram, Charlton, Julie, Pease, Elizabeth, MacDonald, Alexander

Volltext

Multicenter randomized Phase II study of AZD1775 plus chemotherapy versus chemotherapy alone in patients with platinum-resistant TP53-mutated epithelial ovarian, fallopian tube, or... von Moore, Kathleen N., McMeekin, D. Scott, Hamilton, Erika Paige, Strickland, Donald K, Jones, Suzanne Fields, Stults, Dawn Michelle, Laing, Naomi, Spigel, David R., Burris, Howard A.

Volltext

Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tu... von Hurwitz, Herbert, Hainsworth, John D., Swanton, Charles, Perez, Edith A., Sweeney, Christopher, Burris, Howard A., Spigel, David, Meric-Bernstam, Funda, Strickland, Donald K, Leon, Larry, Brammer, Melissa, Beattie, Mary Stanley, Bose, Ron

Volltext

A Phase I Open-Label, Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies von Patel, Manish, Hamlin, Paul, Strickland, Donald K, Pandey, Anjali, Coffey, Greg, Leeds, Janet M, Levy, Gallia G., Curnutte, John T., Wagner-Johnston, Nina, Flinn, Ian W.

Volltext

Abstract CT233: A phase I study evaluating continuous and intermittent AZD2014 in combination with fulvestrant in patients with ER+ advanced metastatic breast cancer von Patel, Manish, Hamilton, Erika, LoRusso, Patricia M., Gluck, W. Larry, Jones, Suzanne F., Kittaneh, Muaiad, Cosulich, Sabina, Harrington, Elizabeth A., Green, Stephen, Burke, Wendy, Strickland, Donald K., Oelmann, Elisabeth, Burris, Howard A.

Volltext

ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC von Bauer, Todd M., Spigel, David, Ready, Neal, Morgensztern, Daniel, Glisson, Bonnie S., Byers, Lauren A., Burris, Howard, Robert, Francisco, Strickland, Donald K., Pietanza, Maria C., Govindan, Ramaswamy, Dylla, Scott J., Peng, Stanford, Rudin, Charles

Volltext

Phase 1 open-label dose escalation study of the dual SYK/JAK inhibitor cerdulatinib (PRT062070) in patients with relapsed/refractory B-cell malignancies: Safety profile and clinica... von Flinn, Ian, Hamlin, Paul A., Strickland, Donald K, Pandey, Anjali, Birrell, Matt, Coffey, Greg, Leeds, Janet, Curnutte, John T, Burger, Jan Andreas, Wagner-Johnston, Nina D., Patel, Manish R.

Volltext

Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell... von Rudin, Charles M., Pietanza, Maria Catherine, Bauer, Todd Michael, Spigel, David R., Ready, Neal, Morgensztern, Daniel, Glisson, Bonnie S., Byers, Lauren Averett, Johnson, Melissa Lynne, Burris, Howard A., Robert, Francisco, Strickland, Donald K, Zayed, Hany, Govindan, Ramaswamy, Dylla, Scott, Peng, Stanford L.

Volltext

Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell... von Rudin, Charles M., Pietanza, Maria Catherine, Bauer, Todd Michael, Spigel, David R., Ready, Neal, Morgensztern, Daniel, Glisson, Bonnie S., Byers, Lauren Averett, Johnson, Melissa Lynne, Burris, Howard A., Robert, Francisco, Strickland, Donald K, Zayed, Hany, Govindan, Ramaswamy, Dylla, Scott, Peng, Stanford L.

Volltext

No-Carrier-Added Iodine-131-FIBG: Evaluation of an MIBG Analog von Vaidyanathan, Ganesan, Zhao, Xiao-Guang, Strickland, Donald K, Zalutsky, Michael R

Volltext

Meta‐[211AT]astatobenzylguanidine: Further evaluation of a potential therapeutic agent von Vaidyanathan, Gunesan, Strickland, Donald K., Zalutsky, Michael R.

Volltext

DYNAMO: A phase 2 trial of the PI3K-δ,γ inhibitor IPI-145 in patients with refractory indolent non-Hodgkin lymphoma von Wagner-Johnston, Nina, Strickland, Donald K, Wright, David Donald, Tetreault, Scott A., Lunin, Scott D., Essell, James H., Webb, Charles D., Langdon, Robert M., Farber, Charles M., Nimeh, Nadim F., Marris, Mike, Coleman, Teresa A., Kelly, Patrick Francis, Steelman, Lori, Dewar, Karen, Pimental, Patricia, Flinn, Ian

Volltext

Hepatitis C infection among survivors of childhood cancer von Strickland, D K, Riely, C A, Patrick, C C, Jones-Wallace, D, Boyett, J M, Waters, B, Fleckenstein, J F, Dean, P J, Davila, R, Caver, T E, Hudson, M M

Volltext